Testosterone Replacement and Hypogonadism: A Brief Review of APIs

 

Testosterone Replacement and Hypogonadism: A Brief Review of APIs that Modify Testosterone’s Metabolism in the Body

Testosterone replacement therapy is currently the standard of treatment for hypogonadism, however, testosterone replacement alone is not always sufficient due to the multiple metabolic pathways involved in the transformation or breakdown of testosterone.1 Testosterone is converted to estradiol via aromatase. Estrogens such as estradiol generate negative feedback to the hypothalamus and pituitary gland reducing the amount of follicle stimulating hormone (FSH) and luteinizing hormone (LH) secreted. This negative feedback loop resulting in reduction of FSH and LH (gonadotropins) decreases testosterone production which can compromise the utility of testosterone therapy alone for hypogonadism.1 Adjunct therapies such as aromatase inhibitors (anastrozole, letrozole etc.) or estrogen receptor antagonists (clomiphene, enclomiphene, tamoxifen, etc.), or GNRH antagonists such as sermorelin are sometimes used instead of or in combination with testosterone supplementation to prevent the negative feedback loop associated with estradiol.1,2 One study evaluating combination treatments with anastrozole and testosterone, concluded that anastrozole given in conjunction with testosterone replacement therapy kept estrogen levels low and attenuated adverse effects typically associated with elevated estrogen levels that can occur with testosterone replacement therapy alone.3 Other studies evaluating clomiphene citrate versus testosterone replacement therapy have noted the benefit of clomiphene for raising testosterone levels and combating hypogonadism.4 Though testosterone is necessary for spermatogenesis, exogenously administered testosterone, in the form of testosterone replacement therapy, can inhibit FSH and LH secretion by the pituitary gland, resulting in decreased spermatogenesis.2 Studies evaluating ingredients that work to prevent this adverse effect on spermatogenesis, including anastrozole and clomiphene among others, have demonstrated efficacy for increasing FSH or LH and improvements in spermatogenesis.4,5,6 To learn more about these active pharmaceutical ingredients (APIs) as well as others used for this purpose, check out a summary table of the listed APIs and the studied dosages and routes for each of these ingredients on our Fagron Academy site!

 

The topics and descriptions discussed within this presentation are not intended and should not be interpreted to make recommendations or claims regarding the use, efficacy, or safety of products, formulas, or vehicles. Only a physician or other appropriately licensed professional, as a learned intermediary, can determine if a formula, product or service is appropriate for a patient

Citations:

1.        Ide V, Vanderschueren D, Antonio L. Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy. Int J Mol Sci. 2020;22(1):21. Published 2020 Dec 22. doi:10.3390/ijms22010021

2.       Rambhatla A, Mills JN, Rajfer J. The Role of Estrogen Modulators in Male Hypogonadism and Infertility. Rev Urol. 2016;18(2):66-72. doi:10.3909/riu0711

3.      Glaser RL, York AE. Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy. Int J Pharm Compd. 2019;23(4):325-339.

4.      Dadhich P, Ramasamy R, Scovell J, Wilken N, Lipshultz L. Testosterone versus clomiphene citrate in managing symptoms of hypogonadism in men. Indian J Urol. 2017;33(3):236-240. doi:10.4103/iju.IJU_372_16

5.      Shoshany O, Abhyankar N, Mufarreh N, Daniel G, Niederberger C. Outcomes of anastrozole in oligozoospermic hypoandrogenic subfertile men. Fertil Steril. 2017;107(3):589-594. doi:10.1016/j.fertnstert.2016.11.021

6.      Taylor F, Levine L. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. J Sex Med. 2010 Jan;7(1 Pt 1):269-76. doi: 10.1111/j.1743-6109.2009.01454.x. Epub 2009 Aug 17.


Comments

Post a Comment

Popular posts from this blog

Guidance for Industry 256: Understanding Impacts on the Compounding Industry

  Guidance for Industry 256: Understanding Impacts on the Compounding Industry By Sarah Taylor, PharmD What is Guidance for Industry (GFI) 256? GFI 256 is a guidance for industry intended to provide clarification from the FDA on compounding animal drugs from bulk drug substances. The guidance does not apply to animal drugs compounded from FDA-approved animal or human drugs, which the FDA generally considers to be legal extra label uses of such drugs. 1 The FDA considers compounding animal drugs from bulk substances by pharmacists and veterinarians to violate aspects of the FD&C Act. Given the wide range of animal species and their varying needs, the FDA acknowledges that in some circumstances there may be no medically appropriate commercially available treatment options or commercially available FDA approved drugs may not be suitable for use as a source of active pharmaceutical ingredient (API) in some circumstances. This guidance lays out the circumstances in which the FDA
Read more

Developing Standard Operating Procedures

Image
 Developing Standard Operating Procedures by Denise M. Frank, RPh, FACA, FAPC   Policies and Procedures are the written pharmacy documents that include the policy statement (a course or plan of action, a high-level principle of the pharmacy), and the procedures for complying or carrying out a task. These procedures are also referred to as Standard Operating Procedures, or SOPs. Why do we need Policies and Procedures, and Standard Operating Procedures (SOPs) for the pharmacy? Policies and procedures will provide for the consistent performance of activities. Personnel have a reference on how to handle situations and perform tasks – working as a team. The manual will very useful when training new employees with clear explanations, instructions, and expectations for specific tasks and for their position. Well-written SOPs also help protect a pharmacy from liability. The policies and procedures, when followed, ensure staff are compliant with regulations and standards and this protects
Read more

Water Activity: USP 795 Changes

  Water Activity: USP <795> Changes Sarah Taylor, PharmD Beyond-use dating in the newly proposed USP General Chapter <795> underwent significant changes, particularly to the recommended maximum beyond-use dates allowed for different types of formulations. One of the biggest changes is a new focus on microbial growth and preservative efficacy. The guidelines define aqueous preparations as those having a water activity (a w ) greater than or equal to 0.6, and only preparations with an a w less than 0.6 are considered anhydrous dosage forms. 1   What is water activity? Water activity is a measurement of the ratio of vapor pressure of the substance in question when at equilibrium with the surrounding air to the vapor pressure of distilled water under identical conditions. 2 So, for example, an a w of 0.6 means that the vapor pressure of the substance in question is 60% that of pure water. Water activity should not be mistaken for water content. Water content is a meas
Read more